The release of GLP-1 is reduced progressively going from normoglycemia, to preT2D and finally to T2D; for this reason, its use for therapeutic purposes is not practicable, except with a continuous infusion. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.